DRIEHAUS CAPITAL MANAGEMENT LLCDRIEHAUS CAPITAL MANAGEMENT LLC

Institutional investor · Portfolio as of Q4 2025

SEC EDGAR SourceSEC Filings

Top Holdings404 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
TSMTSM
ADR

TAIWAN SEMICONDUCTOR SPONSORED ADR /1 ADR REPS 5 ORD SHS/

2.2M$657.5M4.5%$64.83+362.12%
28 qtrssince 2019-Q1
Decreased
0

CRINETICS PHARMACEUTICALS IN

6.4M$297.3M2.0%$26.60+78.13%
23 qtrssince 2020-Q2
Decreased
0

PRAXIS PRECISION MEDICINES I

933,061$275M1.9%$162.36+82.94%
8 qtrssince 2024-Q1
Increased
76

Guardant Health, Inc.

2.1M$218.9M1.5%$44.83+124.39%
4 qtrssince 2025-Q1
Decreased
0

XENON PHARMACEUTICALS INC

4.5M$203.4M1.4%$28.88+52.80%
24 qtrssince 2020-Q1
Increased
53

PLANET LABS PBC

8.5M$167.8M1.1%$9.96+98.28%
3 qtrssince 2025-Q2
Decreased
0

APOGEE THERAPEUTICS INC

2.2M$164.8M1.1%$41.31+83.41%
10 qtrssince 2023-Q3
Increased
48

EOS ENERGY ENTERPRISES INC

14.3M$163.5M1.1%$8.05+41.03%
4 qtrssince 2025-Q1
Increased
77

SITIME CORP

412,873$145.8M1.0%$212.96+70.81%
7 qtrssince 2024-Q2
Decreased
0

NATERA INC

625,912$143.4M1.0%$88.34+160.35%
14 qtrssince 2022-Q3
Increased
46

CAMECO CORP

1.5M$139.3M0.9%$49.70+83.84%
18 qtrssince 2021-Q3
Decreased
0

FTAI AVIATION LTD

700,525$137.9M0.9%$52.86+270.33%
12 qtrssince 2023-Q1
Increased
46

RHYTHM PHARMACEUTICALS INC

1.3M$137.6M0.9%$46.42+129.99%
14 qtrssince 2022-Q3
Decreased
0
HDBHDB
ADR

HDFC BANK LTD-ADR

3.7M$136M0.9%$35.96-35.62%
3 qtrssince 2025-Q2
Increased
49

CREDICORP LTD

472,044$135.5M0.9%$170.02+70.57%
8 qtrssince 2024-Q1
Increased
46

Septerna, Inc.

4.8M$134.1M0.9%$17.10+62.46%
5 qtrssince 2024-Q4
Decreased
0

NU HOLDINGS LTD/CAYMAN ISL-A

7.7M$129M0.9%$15.30+10.36%
3 qtrssince 2025-Q2
Increased
67

BRIDGEBIO PHARMA INC

1.7M$128.6M0.9%$36.00+112.47%
4 qtrssince 2025-Q1
Increased
43

Impinj, Inc.

737,474$128.3M0.9%$176.69-2.82%
2 qtrssince 2025-Q3
Increased
57

CARPENTER TECHNOLOGY

403,296$127M0.9%$217.13+46.65%
6 qtrssince 2024-Q3
Increased
58
$14.7B
AUM
404
Positions
Q4 2025
Filing
Rating · 2.0
Quarterly Portfolio Change
+13%Q3'24$11.6B+4%Q4'24$12.1B-14%Q1'25$10.4B+20%Q2'25$12.5B+12%Q3'25$14B+5%Q4'25$14.7B
Activity profile
$ moved · Q4'25
New18%Increased32%Decreased27%Exited23%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.9 years
<1Q12%1-4Q20%1-2Y15%2Y+53%

DRIEHAUS CAPITAL MANAGEMENT LLC manages $14.7B across 404 positions as of Q4 2025. Top holdings: TSM (4.5%), CRNX (2.0%), PRAX (1.9%). Fund DNA: Momentum Trader. HoldingsIntel Rating: 2/5.0.

Q4 2025 Summary

Active quarter - 89 new positions, 116 exits, 135 increased. Top move: EOSE (INCREASED, conviction 77). Portfolio: $14.7B across 404 positions.

Top holdings by portfolio weight

Total AUM$15B
TSM4.47%
CRNX2.02%
PRAX1.87%
GH1.49%
XENE1.38%
PL1.14%
APGE1.12%
EOSE1.11%
SITM0.99%
NTRA0.97%
Other0.95%

Portfolio allocation by GICS sector

Sectors11
Healthcare29.42%
Industrials21.40%
Technology18.10%
Consumer Cyclical9.17%
Financial Services9.07%
Energy5.01%
Basic Materials3.82%
Consumer Defensive1.70%
Communication Services0.90%
Unknown0.76%
Other0.66%

Behavioral investing profile

Checking access…
Momentum Trader- primarily Healthcare, Industrials, Technology
Compare DNA across all funds
7-dimension quality assessment
Below Average(2.0 / 5.0)
Track Record66
Conviction43
Concentration25
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
EWTXEWTXEDGEWISE THERAPEUTICS INC
Q2 2025 Q2 2026+3.4M shares+$161.9M
5Q
IMAXIMAXIMAX CORP
Q2 2025 Q2 2026+1.9M shares+$82.1M
4Q
IMNMIMNMIMMUNOME INC
Q3 2025 Q2 2026+4.1M shares+$90M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used